TimesSquare Capital Management LLC Has $95.37 Million Position in DexCom, Inc. (NASDAQ:DXCM)

TimesSquare Capital Management LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 768,590 shares of the medical device company’s stock after purchasing an additional 35,210 shares during the period. DexCom comprises 1.4% of TimesSquare Capital Management LLC’s portfolio, making the stock its 15th biggest holding. TimesSquare Capital Management LLC owned about 0.20% of DexCom worth $95,374,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in DXCM. Stableford Capital II LLC increased its stake in shares of DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares in the last quarter. Valley National Advisers Inc. raised its stake in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. FORVIS Wealth Advisors LLC raised its stake in shares of DexCom by 0.7% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after acquiring an additional 110 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its stake in shares of DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after acquiring an additional 115 shares during the last quarter. Finally, HM Payson & Co. raised its stake in shares of DexCom by 8.5% in the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock worth $138,000 after acquiring an additional 116 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the sale, the chief operating officer now owns 273,913 shares in the company, valued at $36,816,646.33. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, COO Jacob Steven Leach sold 14,639 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the sale, the chief operating officer now owns 273,913 shares in the company, valued at approximately $36,816,646.33. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Insiders sold a total of 190,004 shares of company stock worth $25,610,270 over the last quarter. 0.41% of the stock is currently owned by insiders.

DexCom Stock Up 0.6 %

DXCM traded up $0.72 during trading hours on Thursday, hitting $128.14. 1,464,245 shares of the company’s stock were exchanged, compared to its average volume of 2,964,416. The stock has a market cap of $50.96 billion, a price-to-earnings ratio of 82.67, a PEG ratio of 2.19 and a beta of 1.23. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The stock’s 50-day moving average is $133.20 and its two-hundred day moving average is $121.21. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Sell-side analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the subject of a number of recent research reports. Raymond James boosted their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.